Cardiovascular Magnetic Resonance-Guided Radiofrequency-Ablation for

Status Terminated

Clinical Trial Summary

The purpose of this clinical study is to evaluate the and performance of the Imricor Medical Systems, Inc. (Imricor) MR Ablation Catheter when used with related accessories for the treatment of type I atrial flutter. The Vision Ablation Catheter and its accessories have been designed for use under fluoroscopic or magnetic resonance guidance. The study will be a single center study conducted at the Leipzig University Hospital Heart Center in Germany. The study population will consist of adult patients requiring ablation for type I atrial flutter.

Clinical Trial Description

The study will be a single center study conducted at the Leipzig University Hospital Heart Center in Germany. 35 subjects including 5 roll-in subjects meeting inclusion/exclusion criteria will participate in the study. This study requires the use of investigational products from two independent manufacturers: Imricor and Philips. Imricor has developed the ablation catheter with related accessory cables and electrophysiology (EP) recorder/stimulator system. Philips has developed an image guidance and mapping system that is compatible with the Imricor products.

The Vision-MR Ablation Catheter will be used in conjunction with the following investigational products: Advantage-MR EP Recorder/Stimulator, Vision-MR Ablation Cable Set, Vision-MR Diagnostic Cable, the interventional MRI Suite (iSuite) image guidance and mapping system, and a dStream Interface (dSIF-FE). With the exception of iSuite and dSIF-FE, which are manufactured by Philips, Imricor will provide all investigational devices used in the study.

Each procedure will require two single-use Vision-MR Ablation Catheters and one each of the two single-use accessory catheter cables.

Ablation for the treatment of arrhythmia is an inherently complex procedure. Use of the investigational products listed above under MR guidance is an emerging approach to performing the interventional electrophysiology procedure.

The study population will consist of adult patients requiring ablation for type I atrial flutter.

Study subjects will require a follow-up visit or telephone call at seven days post procedure. Accordingly, the expected total study duration is approximately 9 months with study start planned for March 2016. ;

Study Design

Related Conditions & MeSH terms

Atrial Flutter

Clinical Trial Details

NCT number	NCT02699034
Study type	Interventional
Source	University of Leipzig
Contact
Status	Terminated
Phase	N/A
Start date	March 2016
Completion date	October 5, 2016

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05416086` - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study	N/A
Terminated	`NCT02317029` - Comparison of Oxygen Interventions and Defibrillator Efficiency	N/A
Recruiting	`NCT01563848` - Cryoablation in Patients With Atrial Flutter	Phase 2
Completed	`NCT01229254` - Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter	Phase 2
Completed	`NCT00839657` - Clarification of Optimal Anticoagulation Through Genetics	Phase 3
Completed	`NCT02065388` - Pharmacogenetic Dosing of Warfarin	Phase 3
Completed	`NCT00232232` - Use of Fish Oils to Prevent Atrial Mechanical Stunning and Atrial Remodeling Due to Atrial Arrhythmia	Phase 4
Completed	`NCT04884100` - enHEART - Exploring Full Content of Optical Signals to Enhance Cardiac Arrhythmia Screening	N/A
Completed	`NCT05468281` - RAFF5 Proposal: Improve the Quality and Safety of Patients Seen in the Emergency Department for Acute Atrial Fibrillation and Flutter
Completed	`NCT03627143` - Decreasing Hospital Admissions From the ED for AAFF	N/A
Completed	`NCT02917538` - A Randomized Trial of Contact Force in Atrial Flutter Ablation	N/A
Enrolling by invitation	`NCT05903313` - A Study to Evaluate Accuracy and Validity of the Chang Gung ECG Abnormality Detection Software
Recruiting	`NCT05755074` - Ablation of Typical Right Atrial Flutter	N/A
Recruiting	`NCT05883631` - RESOLVE-AF: Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Sources of Atrial Fibrillation and Guide Ablation Therapy.	N/A
Recruiting	`NCT03272620` - Atrial Fibrillation at the Viennese University Emergency Department	N/A
Completed	`NCT02810938` - MIFI Flutter Registry - Ablation of Atrial Flutter With IntellaTip Sensor Technology
Recruiting	`NCT02591875` - Atrial Flutter Ablation in a Real World Population	N/A
Completed	`NCT01914497` - Dipole Density Mapping of Typical Atrial Flutter	N/A
Completed	`NCT02268799` - High Sensitivity Troponin T Levels Following DC Cardioversion for Atrial Fibrillation / Atrial Flutter	N/A
Active, not recruiting	`NCT01976507` - Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Cardiovascular Magnetic Resonance-Guided Radiofrequency-Ablation for Atrial Flutter

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms